Drug Profile
Carbon-11-MK 6884 - Merck Sharp & Dohme
Alternative Names: [11C]MK-6884; C-11-MK-6884; MK-6884Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antidementias; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2022 No development reported - Phase-II for Alzheimer's disease (Diagnosis, In the elderly) in USA (IV)
- 31 Jul 2022 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2022 (AAIC-2022)
- 25 Apr 2020 Phase-II clinical trials in Alzheimer's disease (Diagnosis, In the elderly) in USA (IV) before April 2020